

others, we stand ready to support in any way we can and welcome the continued dialogue. We have made headway through securing our vaccine clinical trials investment here in the Netherlands, so you will see signs of that in the new year. We are committed to offering affordable and accessible vaccines and medicines, as always.

I would appreciate a chance early in the new year to update you on the progress of our programme, for instance when it comes our research to find treatments that will improve outcomes for COVID patients in various stages of illness and possibly reduce the burden on the health system. As you are aware, MSD has currently two vaccines and two treatments in far stages of development.

I look forward to progressing the discussion on potential COVID treatments early in the new year as we expect new developments by then and in the meantime offer you, your loved ones and your families, good health and a Happy Christmas

Your sincerely,

5.1.2e

MSD BV

[Waarderweg 39](#), 2031 BN Haarlem, The Netherlands
P.O. Box 581, 2003 PC Haarlem, The Netherlands

Notice: This e-mail message, together with any attachments, contains information of Merck & Co., Inc. (2000 Galloping Hill Road, Kenilworth, New Jersey, USA 07033), and/or its affiliates Direct contact information for affiliates is available at <http://www.merck.com/contact/contacts.html>) that may be confidential, proprietary copyrighted and/or legally privileged. It is intended solely for the use of the individual or entity named on this message. If you are not the intended recipient, and have received this message in error, please notify us immediately by reply e-mail and then delete it from your system.